MCID: MYL003
MIFTS: 49

Myeloid Sarcoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Myeloid Sarcoma

MalaCards integrated aliases for Myeloid Sarcoma:

Name: Myeloid Sarcoma 12 52 58 15 17 32
Granulocytic Sarcoma 12 52 58 17 71
Extramedullary Myeloid Tumor 12 52 58
Chloroma 12 52 58
Sarcoma, Granulocytic 74
Sarcoma Granulocytic 54
Sarcoma, Myeloid 43

Characteristics:

Orphanet epidemiological data:

58
myeloid sarcoma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8683
MeSH 43 D023981
NCIt 49 C35815
SNOMED-CT 67 188738007
ICD10 32 C92.3
MESH via Orphanet 44 D023981
ICD10 via Orphanet 33 C92.3
UMLS via Orphanet 72 C0152276
Orphanet 58 ORPHA86850
UMLS 71 C0152276

Summaries for Myeloid Sarcoma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 86850 Definition Myeloid sarcoma is a rare solid tumor of the myelogenous cells occurring in an extramedullary site. Epidemiology The exact prevalence is unknown. Clinical description The clinical presentation depends on the site of involvement. Commonly involved sites of occurrence include the subperiosteal bone structures of the skull, paranasal sinuses, sternum, ribs, vertebrae, pelvis, as well as the lymph nodes and skin. Rare sites include the pancreas, heart, brain, mouth, breast, gastrointestinal and biliary tract, prostate, urinary bladder and gynecologic tract. Visit the Orphanet disease page for more resources.

MalaCards based summary : Myeloid Sarcoma, also known as granulocytic sarcoma, is related to acute myeloblastic leukemia with maturation and childhood acute myeloid leukemia. An important gene associated with Myeloid Sarcoma is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Fludarabine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and breast, and related phenotypes are hematopoietic system and cellular

Wikipedia : 74 A myeloid sarcoma (chloroma, granulocytic sarcoma, extramedullary myeloid tumor), is a solid tumor... more...

Related Diseases for Myeloid Sarcoma

Diseases related to Myeloid Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 495)
# Related Disease Score Top Affiliating Genes
1 acute myeloblastic leukemia with maturation 30.9 NPM1 KIT FLT3
2 childhood acute myeloid leukemia 30.7 NPM1 KIT FLT3
3 acute myeloblastic leukemia without maturation 30.5 NPM1 FLT3
4 monocytic leukemia 30.4 MPO KMT2A FLT3
5 acute myeloid leukemia with t(8;21)(q22;q22) translocation 30.4 KIT FLT3
6 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.1 MPO KMT2A KIT FLT3 DNTT
7 exanthem 30.1 MPO KIT CD274
8 thymoma 30.1 PTPRC KIT DNTT CD274
9 extracutaneous mastocytoma 30.1 U2AF1 KIT
10 small intestinal sarcoma 30.1 PTPRC KIT CD68
11 lymphoblastic lymphoma 30.0 PTPRC PAX5 MPO KMT2A DNTT
12 lymphoplasmacytic lymphoma 30.0 PTPRC PAX5 IRF4
13 mediastinal malignant lymphoma 30.0 PAX5 CD79A
14 anaplastic large cell lymphoma 29.9 PTPRC PAX5 NPM1 IRF4
15 hodgkin's lymphoma, nodular sclerosis 29.9 PTPRC PAX5 CD79A
16 dendritic cell tumor 29.8 PTPRC MPO DNTT CD68
17 peripheral t-cell lymphoma 29.8 PTPRC PAX5 NCAM1 CD274
18 cll/sll 29.7 SPN PAX5 CD79A
19 myeloproliferative neoplasm 29.7 U2AF1 MPO KMT2A KIT FLT3 ANPEP
20 central nervous system leukemia 29.7 CD34 CD33 ANPEP
21 chronic eosinophilic leukemia 29.7 U2AF1 KIT FLT3
22 leukemia 29.7 U2AF1 PAX5 NPM1 KMT2A KIT FLT3
23 lymphoma, hodgkin, classic 29.7 PTPRC PAX5 IRF4 CD68
24 liver sarcoma 29.6 CD68 CD34
25 testicular lymphoma 29.5 IRF4 CD79A CD274
26 myeloid leukemia 29.5 U2AF1 NPM1 MPO KMT2A KIT FLT3
27 germinoma 29.5 U2AF1 PAX5 KIT
28 mast cell neoplasm 29.4 U2AF1 KIT FLT3 CD34
29 reticulosarcoma 29.4 PTPRC PAX5 NPM1 CD68 ANPEP
30 aleukemic leukemia cutis 29.4 SPN NPM1 MPO CD33 ANPEP
31 angiosarcoma 29.4 KIT CD68 CD34
32 ewing sarcoma 29.3 PTPRC NCAM1 KIT DNTT CD34
33 langerhans cell histiocytosis 29.2 U2AF1 PTPRC CD68
34 myelofibrosis 29.2 U2AF1 NPM1 MPO KIT FLT3 CD34
35 myelodysplastic/myeloproliferative neoplasm 29.2 U2AF1 KMT2A KIT FLT3
36 b-cell lymphoma 29.2 PTPRC PAX5 NPM1 MIR181A1 IRF4 CD274
37 leukemia, acute lymphoblastic 3 29.1 PAX5 MPO KMT2A FLT3 DNTT CD34
38 megakaryocytic leukemia 29.1 U2AF1 MPO KMT2A
39 lymphoma 29.1 PTPRC PAX5 NPM1 KIT IRF4 DNTT
40 deficiency anemia 29.0 U2AF1 KIT CD34 ANPEP
41 leukemia, acute monocytic 29.0 U2AF1 MPO KMT2A FLT3 CD33
42 chronic leukemia 29.0 U2AF1 KIT FLT3 CD34
43 plasmacytoma 28.9 PTPRC PAX5 NCAM1 IRF4 CD79A
44 lymphoma, mucosa-associated lymphoid type 28.9 SPN PTPRC PAX5 IRF4 CD79A
45 suppression of tumorigenicity 12 28.8 U2AF1 PTPRC NCAM1 KIT CD274
46 chronic myelomonocytic leukemia 28.8 U2AF1 NPM1 MPO KMT2A KIT FLT3
47 basal cell carcinoma 28.8 NCAM1 KIT CD68 CD34 CD274
48 precursor t-cell acute lymphoblastic leukemia 28.7 MPO KMT2A FLT3 DNTT CD34 CD33
49 mixed phenotype acute leukemia 28.5 U2AF1 MPO KMT2A DNTT CD33 ANPEP
50 acute leukemia 28.5 PAX5 NPM1 NCAM1 MPO KMT2A KIT

Graphical network of the top 20 diseases related to Myeloid Sarcoma:



Diseases related to Myeloid Sarcoma

Symptoms & Phenotypes for Myeloid Sarcoma

MGI Mouse Phenotypes related to Myeloid Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 ANPEP CD274 CD34 CD68 CD79A DNTT
2 cellular MP:0005384 10.06 CD274 CD34 CD79A FLT3 IRF4 KIT
3 immune system MP:0005387 10.06 ANPEP CD274 CD34 CD68 CD79A DNTT
4 neoplasm MP:0002006 9.65 CD34 CD79A FLT3 IRF4 KIT KMT2A
5 no phenotypic analysis MP:0003012 9.17 CD274 CD68 CD79A FLT3 KIT KMT2A

Drugs & Therapeutics for Myeloid Sarcoma

Drugs for Myeloid Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
5
Thioguanine Approved Phase 3 154-42-7 2723601
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Idarubicin Approved Phase 3 58957-92-9 42890
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
9
Busulfan Approved, Investigational Phase 3 55-98-1 2478
10
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
11
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
12
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
15
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
16
Etoposide Approved Phase 3 33419-42-0 36462
17
Daunorubicin Approved Phase 3 20830-81-3 30323
18
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
19
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
22
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
23 Vitamin B Complex Phase 3
24 Folate Phase 3
25 Vitamin B9 Phase 3
26 Anti-HIV Agents Phase 3
27 Analgesics, Non-Narcotic Phase 3
28 Alkylating Agents Phase 3
29 Interleukin-2 Phase 3
30 Antirheumatic Agents Phase 3
31 Anti-Retroviral Agents Phase 3
32 Gastrointestinal Agents Phase 3
33 Hormones Phase 3
34 Antineoplastic Agents, Hormonal Phase 3
35 Antiemetics Phase 3
36 Hormone Antagonists Phase 3
37 glucocorticoids Phase 3
38 Anti-Inflammatory Agents Phase 3
39 Hydrocortisone 17-butyrate 21-propionate Phase 3
40 Hydrocortisone-17-butyrate Phase 3
41 Folic Acid Antagonists Phase 3
42 Hydrocortisone hemisuccinate Phase 3
43 BB 1101 Phase 3
44 Immunologic Factors Phase 3
45 Anti-Infective Agents Phase 3
46 Antiviral Agents Phase 3
47 Immunosuppressive Agents Phase 3
48 Analgesics Phase 3
49 Antimetabolites Phase 3
50 Antibiotics, Antitubercular Phase 3

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
2 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
3 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD Active, not recruiting NCT01371981 Phase 3 Asparaginase;Bortezomib;Cytarabine;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone Hydrochloride;Sorafenib Tosylate
4 Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms Recruiting NCT03589729 Phase 2 Cladribine;Cytarabine;Dexrazoxane Hydrochloride;Gemtuzumab Ozogamicin;Idarubicin
5 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting NCT02790515 Phase 2 Anti-thymocyte globulin (rabbit);Blinatumomab;Cyclophosphamide;Fludarabine;G-CSF;Melphalan;Mesna;Rituximab;Tacrolimus;Thiotepa;Sirolimus
6 An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Active, not recruiting NCT02484391 Phase 2 6,8-Bis(benzylthio)octanoic Acid;Cytarabine;Mitoxantrone Hydrochloride
7 Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML Active, not recruiting NCT02658487 Phase 2 Cytarabine;Vosaroxin
8 Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML Active, not recruiting NCT02770820 Phase 1, Phase 2
9 CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Terminated NCT02259348 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Thiotepa;Rituximab
10 T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated NCT01621477 Phase 2 clofarabine;cytarabine;busulfan;Plerixafor;cyclophosphamide;antithymocyte globulin (rabbit);Tacrolimus;mycophenolate mofetil
11 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803 Recruiting NCT02890758 Phase 1
12 PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations Completed NCT01278069
13 Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): an Observational Retrospective Multicentre Study on Patients Previously Registered in GIMEMA Clinical Trials Not yet recruiting NCT03410407
14 Clinical and Immunological Outcome in Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor: Assuit University Hospitals Insight Not yet recruiting NCT03907670

Search NIH Clinical Center for Myeloid Sarcoma

Cochrane evidence based reviews: sarcoma, myeloid

Genetic Tests for Myeloid Sarcoma

Anatomical Context for Myeloid Sarcoma

MalaCards organs/tissues related to Myeloid Sarcoma:

40
Myeloid, Bone, Breast, Bone Marrow, Skin, Lymph Node, T Cells

Publications for Myeloid Sarcoma

Articles related to Myeloid Sarcoma:

(show top 50) (show all 1707)
# Title Authors PMID Year
1
The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. 61 54
18794057 2008
2
Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): a case study and review of the literature. 61 54
18656695 2008
3
t(5;12)(q13;p13) in acute myeloid leukemia with preceding granulocytic sarcoma. 54 61
17854675 2007
4
Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literature. 61 54
17700206 2007
5
Granulocytic sarcoma of breast: an aleukemic presentation. 54 61
17337816 2007
6
Myeloid sarcoma occurring concurrently with drug-induced gingival enlargement. 61 54
16579712 2006
7
Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation. 54 61
15621793 2005
8
[A-leukemic caecal myeloid sarcoma: a difficult diagnosis]. 61 54
15738870 2004
9
FLT3 mutations in myeloid sarcoma. 61 54
15352981 2004
10
Extramedullary presentation of acute leukaemia: a case of myeloid/natural killer cell precursor leukaemia. 54 61
12959763 2003
11
Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement. 61 54
11733351 2001
12
c-Kit (CD117) reactivity in extramedullary myeloid tumor/granulocytic sarcoma. 61 54
11698000 2001
13
The value of CD34, myeloperoxidase and chloroacetate esterase (Leder) stain in the diagnosis of granulocytic sarcoma. 61 54
17261930 2001
14
[Granulocytic sarcoma presenting as an epidural mass with spinal cord compression]. 61 54
11020993 2000
15
CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature. 61 54
11138613 2000
16
Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. 54 61
8902835 1996
17
Granulocytic sarcoma with expression of CD30. 54 61
9038763 1996
18
Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. 61 54
8907283 1996
19
Extramedullary tumors of lymphoid or myeloid blasts. The role of immunohistology in diagnosis and classification. 61 54
7572794 1995
20
Immunohistochemical differential diagnosis of granulocytic sarcomas and malignant lymphomas on formalin-fixed material. 54 61
2106752 1990
21
Myelodysplastic syndrome presenting with generalized cutaneous granulocytic sarcomas. 61 54
2154905 1990
22
Granulocytic Sarcoma: A Rare Cause of Wrist Pain. 61
32149843 2020
23
Gastric myeloid sarcoma with rapid growth. 61
32567724 2020
24
Donor-derived acute promyelocytic leukemia presenting as myeloid sarcoma in a transplanted kidney. 61
32523036 2020
25
Dark as night: Spelunking for spinal solitary fibrous tumors/hemangiopericytomas in the differential of T2 hypointensity. 61
32507710 2020
26
Myeloid sarcoma on the temporal region before the onset of the acute myeloid leukemia: an extremely rare case report. 61
31970569 2020
27
Characteristics of myeloid sarcoma in mice and patients with TET2 deficiency. 61
32382331 2020
28
Granulocytic sarcoma causing long spinal cord compression: Case report and literature review. 61
32543308 2020
29
Somatic ASXL1 p.R693X mutation identified by next generation sequencing in isolated myeloid sarcoma involving the mediastinum. 61
32286099 2020
30
Pancreatic Myeloid Sarcoma. 61
32528784 2020
31
Diagnostic and Therapeutic Considerations for Extramedullary Leukemia. 61
32577912 2020
32
Reply to Letter to the Editor commenting on the article "Myeloid sarcoma on the temporal region before the onset of the acute myeloid leukemia: an extremely rare case report". 61
32382855 2020
33
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. 61
30543582 2020
34
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. 61
32065308 2020
35
Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent. 61
32375463 2020
36
Epidural myeloid sarcoma as the presenting symptom of chronic myeloid leukemia blast crisis. 61
32458246 2020
37
Review on gall bladder myeloid sarcoma: a great masquerader. 61
32434344 2020
38
Uterine myeloid sarcoma. 61
32367177 2020
39
Myeloid sarcoma with epigastric pain as initial manifestation. 61
31943771 2020
40
Temporal region myeloid sarcoma: When to suspect and how to approach? 61
32399657 2020
41
Placental myeloid sarcoma. 61
32298443 2020
42
[Myeloid sarcoma]. 61
32353885 2020
43
Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia. 61
31688618 2020
44
Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemia. 61
31919567 2020
45
Isolated intracranial myeloid sarcoma: report of a case and review of the literature. 61
32351132 2020
46
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. 61
32170661 2020
47
A case of myeloid sarcoma of the mandibular gingiva as extramedullary relapse of acute myeloid leukemia. 61
31788742 2020
48
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor. 61
32163103 2020
49
[Clinicopathological features of myeloid sarcoma and DLBCL in the breast: a comparative study]. 61
32187897 2020
50
Myeloid sarcoma. 61
31904666 2020

Variations for Myeloid Sarcoma

Expression for Myeloid Sarcoma

Search GEO for disease gene expression data for Myeloid Sarcoma.

Pathways for Myeloid Sarcoma

GO Terms for Myeloid Sarcoma

Cellular components related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 SPN PTPRC NCAM1 KIT CD34 CD274
2 external side of plasma membrane GO:0009897 9.23 PTPRC NCAM1 KIT CD79A CD34 CD33

Biological processes related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.88 PTPRC NPM1 NCAM1 FLT3 ANPEP
2 neutrophil degranulation GO:0043312 9.77 PTPRC MPO CD68 CD33 ANPEP
3 MAPK cascade GO:0000165 9.73 PEBP1 NCAM1 KIT FLT3
4 hematopoietic progenitor cell differentiation GO:0002244 9.58 PTPRC KIT FLT3
5 hemopoiesis GO:0030097 9.5 KIT FLT3 CD34
6 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.46 PTPRC IRF4
7 negative regulation of tumor necrosis factor production GO:0032720 9.43 MIR181A1 CD34 CD33
8 myeloid progenitor cell differentiation GO:0002318 9.16 KIT FLT3
9 positive regulation of protein tyrosine phosphatase activity GO:1903615 8.96 PTPRC CD33
10 B cell differentiation GO:0030183 8.92 PTPRC KIT FLT3 CD79A

Sources for Myeloid Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....